Upcoming FDA advisory committee meetings
Executive Summary
Oncology Drugs Advisory Committee will meet April 19, 8:30 a.m. at the Parklawn Building to discuss use of Bristol-Myers' ifosfamide for use in combination with other approved cytotoxic drugs for treatment of testicular cancer; Dermatologic Drugs Advisory Committee's April 26 meeting (8:30 a.m. at Parklawn) will address adverse effects of Roche's Accutane (isotretinoin); Pulmonary-Allergy Drugs Advisory Committee agenda at April 28-29 meeting includes the new drug evaluation review process, use of caffeine for apnea of prematurity, and data supporting pediatric use of inhaled albuterol.